Mark Terrelonge, MD, MPH
Assistant Professor
Neurology
School of Medicine

Mark Terrelonge MD MPH is an Assistant Professor of Neurology and Neuromuscular Medicine at the University of California San Francisco and Assosciate Program Director of the UCSF Neurology Residency. He sees patients with disorders of the nerve, muscle, neuromuscular junction, and spine.

Show full bio (37 words) Hide full bio

He also cares for general Neurology patients at the Zuckerberg San Francisco General Hospital, and Neuromuscular and ALS patients in the Fresno region. He has a special interest in patients from rural and underserved areas of California.

Awards

Show all (5) Hide

• Cheryl Jay Master Clinician Award for Clinical Excellence in Neurology, UCSF, 2023
• Haile T. Debas Academy of Medical Educators School of Medicine Excellence in Teaching Award, UCSF, 2023
• John A. Watson Faculty Scholar, UCSF, 2020
• Alpha Omega Alpha, UCSF, 2019
• UCSF Teaching Excellence Award for Cherished Housestaff, UCSF, 2017

Education & Training

Show all (6) Hide

• Diversity, Equity, and Inclusion Champion Training University of California San Francisco 09/2020
• Fellowship Neuromuscular Medicine University of California San Francisco 06/2020
• Resident Neurology University of California San Francisco 06/2019
• MD Stanford School of Medicine 06/2015
• MPH Biostatistics Columbia Mailman School of Public Health 10/2014
• BA Neurobiology Harvard University 06/2010

Interests

Show all (9) Hide

• ALS
• Myasthenia Gravis
• Neuromuscular Disease
• Motor Neuron Disease
• Neurology
• Muscle Disease
• Access to Care
• Medical Education
• Neuromuscular Junction Disorders

Videos

Show all (1) Hide

• Mark Terrelonge, MD, MPH: 2020 Watson Scholar (youtube.com)

Publications (9)

Top publication keywords:
Receptor, Melatonin, MT2Postoperative ComplicationsParkinson DiseaseParaneoplastic Cerebellar DegenerationAmyloid beta-PeptidesDeliriumCognition DisordersAmyotrophic Lateral SclerosisGenotypePolymorphism, Single NucleotidePeripheral Nervous System DiseasesTacrolimus Binding ProteinsPeptide FragmentsNerve Compression SyndromesDiet, Ketogenic

• Severe Adult-Onset Non-Dystrophic Myotonia With Apnea and Laryngospasm Due to Digenic Inheritance of SCN4A and CLCN1 Variants: A Case Report.
  Neurology. Genetics 2024 Tugizova M, Margeta M, Richie M, Pet D, Rosow L, Terrelonge M, Ralph JW
• Needs assessment for direct ophthalmoscopy training in neurology residency.
  BMC medical education 2024 Saroya J, Chahal N, Jiang A, Pet D, Rasool N, Terrelonge M, Yung M
• Detection of High-Risk Paraneoplastic Antibodies against TRIM9 and TRIM67 Proteins.
  Annals of neurology 2023 Bartley CM, Ngo TT, Do LD, Zekeridou A, Dandekar R, Muñiz-Castrillo S, Alvarenga BD, Zorn KC, Tubati A, Pinto AL, Browne WD, Hullett PW, Terrelonge M, Schubert RD, Piquet AL, Yang B, Montalvo M, Kung …
• ALSUntangled #65: glucocorticoid corticosteroids.
  Amyotrophic lateral sclerosis & frontotemporal degeneration 2022 Goslinga JA, Terrelonge M, Bedlack R, Barkhaus P, Barnes B, Bertorini T, Bromberg M, Carter G, Chen A, Crayle J, Dimachkie M, Jiang L, Levitsky G, Lund I, Martin S, Mcdermott C, Pattee G, Pierce K, …
• Common Focal Neuropathies in the Hospitalized Patient.
  Neurologic clinics 2022 Terrelonge M, Rosow L

Show all (4 more) Hide

• KIBRA, MTNR1B, and FKBP5 genotypes are associated with decreased odds of incident delirium in elderly post-surgical patients.
  Scientific reports 2022 Terrelonge M, LaHue SC, Tang C, Movsesyan I, Pullinger CR, Dubal DB, Leung J, Douglas VC
• ALSUntangled #63: ketogenic diets.
  Amyotrophic lateral sclerosis & frontotemporal degeneration 2021 Bedlack R, Barkhaus PE, Barnes B, Beauchamp M, Bertorini T, Bromberg MB, Carter GT, Chaudry V, Cudkowicz M, Jackson C, Levitsky G, Lund I, McDermott C, Novella S, Olby N, Ostrow L, Pattee GL, Heiman-…
• Outcomes Following Implementation of a Hospital-Wide, Multicomponent Delirium Care Pathway.
  Journal of hospital medicine 2021 LaHue SC, Maselli J, Rogers S, Casatta J, Chao J, Croci R, Gonzales R, Holt B, Josephson SA, Lama S, Lau C, McCulloch C, Newman JC, Terrelonge M, Yeager J, Douglas VC
• CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease.
  Journal of molecular neuroscience : MN 2015 Terrelonge M, Marder KS, Weintraub D, Alcalay RN